Publication:
Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort

dc.contributor.authorİdilman, Ramazan
dc.contributor.authorDemir, Mehmet
dc.contributor.authorAladağ, Murat
dc.contributor.authorErol, Cihan
dc.contributor.authorÇavuş, Bilger
dc.contributor.authorİliaz, Raim
dc.contributor.authorKöklü, Hayrettin
dc.contributor.authorÇakaloğlu, Yılmaz
dc.contributor.authorŞahin, Memduh
dc.contributor.authorErsöz, Galip
dc.contributor.authorKöksal, İftihar
dc.contributor.authorKarasu, Zeki
dc.contributor.authorÖzgenel, Meriç
dc.contributor.authorTuran, İlker
dc.contributor.authorGündüz, Feyza
dc.contributor.authorAtaseven, Hüseyin
dc.contributor.authorAkdoğan, Meral
dc.contributor.authorKıyıcı, Murat
dc.contributor.authorKöksal, Aydın Şeref
dc.contributor.authorAkhan, Sila
dc.contributor.authorGünsar, Fülya
dc.contributor.authorTabak, Fehmi
dc.contributor.authorKaymakoglu, Sabahattin
dc.contributor.authorAkarca, Ulus S.
dc.contributor.authorAkarsu, Mesut
dc.contributor.authorAlkim, Hüseyin
dc.contributor.authorAraz, Filiz
dc.contributor.authorAteş, Fehmi
dc.contributor.authorAygen, Bilgehan
dc.contributor.authorBalık, İsmail
dc.contributor.authorBarut, Hüseyin S.
dc.contributor.authorBaysal, Birol
dc.contributor.authorBolat, Aylin
dc.contributor.authorÇelik, İlhami
dc.contributor.authorCoşgun, Süleyman
dc.contributor.authorEnsaroglu, Fatih
dc.contributor.authorGökcan, Hale
dc.contributor.authorGürel, Selim
dc.contributor.authorGürsoy, Şebnem
dc.contributor.authorİnkaya, Ahmet Çağan
dc.contributor.authorKamilli, Cemil
dc.contributor.authorKav, Taylan
dc.contributor.authorKuruüzüm, Ziya
dc.contributor.authorÖnder, Fatih O.
dc.contributor.authorÖrmeci, Necati
dc.contributor.authorÖzbakır, Ömer
dc.contributor.authorÖzenirler, Seren
dc.contributor.authorÖzer, Birol
dc.contributor.authorÖzkan, Hasan
dc.contributor.authorPoturoğlu, Şule
dc.contributor.authorSenates, Ebubekir
dc.contributor.authorŞimşek, Halis
dc.contributor.authorToka, Bilal
dc.contributor.authorÜnal, Hakan
dc.contributor.authorYaras, Serkan
dc.contributor.authorYıldırım, Abdullah E.
dc.contributor.authorYıldırım, Beytullah
dc.contributor.authorYılmaz, Bülent
dc.contributor.authorYılmaz, Hasan
dc.contributor.authorYozgat, Ahmet
dc.contributor.authorYurdaydın, Cihan
dc.contributor.authorEarly Access Program EAP Study Grp
dc.contributor.buuauthorKIYICI, MURAT
dc.contributor.departmentBursa Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı
dc.contributor.orcid0000-0002-3208-6211
dc.contributor.researcheridAAI-4213-2021
dc.date.accessioned2024-07-24T10:45:55Z
dc.date.available2024-07-24T10:45:55Z
dc.date.issued2019-06-01
dc.description.abstractThe aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease and to analyse whether the use of LDV/SOF treatment is associated with a new occurrence of hepatocellular carcinoma (HCC) during and after LDV/SOF treatment. The Turkish Early Access Program provided LDV/SOF treatment to a total of 200 eligible CHC patients with advanced liver disease. The median follow-up period was 22months. All patients were Caucasian, 84% were infected with genotype 1b, and 24% had a liver transplantation before treatment. The sustained virological response (SVR12) was 86.0% with ITT analysis. SVR12 was similar among patients with Child-Pugh classes A, B and C disease and transplant recipients. From baseline to SVR12, serum ALT level and MELD score were significantly improved (P<0.001). LDV/SOF treatment was generally well tolerated. Only one patient developed a new diagnosed HCC. Seventeen of the 35 patients, who had a history of previous HCC, developed HCC recurrence during the LDV/SOF treatment or by a median follow-up of 6months after treatment. HCC recurrence was less commonly observed in patients who received curative treatment for HCC compared with those patients who received noncurative treatment (P=0.007). In conclusion, LDV/SOF with or without ribavirin is an effective and tolerable treatment in CHC patients with advanced liver disease. Eradication is associated with improvements in liver function and a reduced risk of developing a new occurrence of HCC.Ledipasvir and sofosbuvir with or without ribavirin is an effective and tolerable treatment in hepatitis C virus-infected patients with advanced liver disease. Eradication is associated with improvements in liver function and reduces the risk of developing a new occurrence of hepatocellular carcinoma.
dc.identifier.doi10.1111/jvh.13075
dc.identifier.eissn1365-2893
dc.identifier.endpage674
dc.identifier.issn1352-0504
dc.identifier.issue6
dc.identifier.startpage666
dc.identifier.urihttps://doi.org/10.1111/jvh.13075
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/10.1111/jvh.13075
dc.identifier.urihttps://hdl.handle.net/11452/43412
dc.identifier.volume26
dc.identifier.wos000469027000006
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherWiley
dc.relation.journalJournal of Viral Hepatitis
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectSustained virological response
dc.subjectUnexpected high-incidence
dc.subjectActing antiviral therapy
dc.subjectAll-cause mortality
dc.subjectVirus-infection
dc.subjectPlus ribavirin
dc.subjectRisk-factors
dc.subjectGenotype 1
dc.subjectLiver
dc.subjectHcv
dc.subjectCirrhosis
dc.subjectDirect-acting antivirals
dc.subjectHepatitis c virus
dc.subjectHepatocellular carcinoma
dc.subjectLiver transplantation
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectGastroenterology & hepatology
dc.subjectInfectious diseases
dc.subjectVirology
dc.titleLow recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort
dc.typeArticle
dspace.entity.typePublication
relation.isAuthorOfPublicationb364b52b-c416-4987-b080-93f6f81ecb3e
relation.isAuthorOfPublication.latestForDiscoveryb364b52b-c416-4987-b080-93f6f81ecb3e

Files

Collections